Peptide Encyclopedia / N-Acetyl Selank Amidate
EncyclopediaN-Acetyl Selank Amidate is a modified analog of Selank, a synthetic heptapeptide from tuftsin, with acetylation and amidation for stability and proposed anxiolytic and nootropic effects. The FDA has not approved it, it trades gray-market in the US, and the analog rests on minimal human data. Educational only, not medical advice.
| Category | Cognitive |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A chemically modified analog of Selank, a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin. N-acetylation and C-amidation are intended to improve stability. Selank is proposed to act as an anxiolytic/nootropic via modulation of GABAergic and monoaminergic signaling and effects on BDNF and enkephalin metabolism.
uncertain / limited human pharmacokinetic data; native Selank is short-acting, and the modified analog's PK has not been characterized in peer-reviewed human studies.
Not FDA-approved; research chemical / gray-market in the US. The parent compound Selank is a registered/approved anxiolytic drug in Russia (approved ~2009) but is not approved outside Russia/CIS. The N-acetyl amidate analog is not an approved drug anywhere.
Human safety data for the modified analog are minimal. Russian data on parent Selank report a favorable short-term tolerability profile (non-sedating, no clear dependence); long-term and analog-specific safety are unknown. Gray-market product identity/purity is unverified.
Parent Selank has Russian clinical trials (anxiety) but little independent Western replication; the specific N-acetyl amidate analog has minimal published human data and rests largely on vendor claims and extrapolation from Selank.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. N-Acetyl Selank Amidate may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
